Apolipoprotein E Polymorphism in Omani Dyslipidemic Patients With and Without Coronary Artery Disease

• Published in: Human biology Vol. 79; no. 1; pp. 93 - 102
• Main Authors: Al-Yahyaee, Said Ali S., Ganguly, Shyam Sundar, Al-Kindi, Mohammed Nasser, Al-Bahrani, Ali Ihassan
• Format: Journal Article
• Language: English
• Published: United States Wayne State University Press 01.02.2007
• Subjects: Adult; Aged; Alleles; Angina pectoris; APOLIPOPROTEIN E (APOE) POLYMORPHISM; Apolipoprotein E2 - genetics; Apolipoprotein E3 - genetics; Apolipoprotein E4 - genetics; Apolipoproteins; Biochemistry; Blood pressure; Cardiovascular disease; Cholesterol; Cholesterols; Computer aided design; CORONARY ARTERY DISEASE; Coronary Disease - genetics; Coronary heart disease; DNA polymerase; DYSLIPIDEMIA; Dyslipidemias; Dyslipidemias - complications; Dyslipidemias - genetics; Female; Gene Frequency; Genetic aspects; Genetic polymorphisms; Genetics, Population - methods; Genotypes; Homozygote; Humans; Lipids; Lipids - blood; Lipoproteins; Low density lipoprotein; Male; Middle Aged; Mortality; Observations; Oman; OMANI POPULATION; Patients; Plasma; Polymerase Chain Reaction; Polymorphism; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Properties; Retrospective Studies; Risk factors; s; Thyroid diseases; Vein & artery diseases; Oman
• ISSN: 0018-7143; 1534-6617; 1534-6617
• DOI: 10.1353/hub.2007.0020

Apolipoprotein E (APOE) polymorphism is a predictor of interindividual variability in plasma levels of lipids and lipoproteins and a predictor of risk of coronary artery disease (CAD). We studied the relationship between APOE polymorphism and lipid profiles and risk of CAD in Omani dyslipidemic patients. This retrospective study included 244 dyslipidemic patients, of whom 67 had CAD. Fasting blood glucose, lipids, and plasma lipoprotein levels were measured using standard methods, and APOE genotypes were detected by PCR-RFLP. The dyslipidemic patients had the following APOE allele frequencies: APOE*2, 0.030; APOE*3, 0.894; and APOE*4, 0.076. APOE allele frequencies between patients with and without CAD showed no significant differences. Compared to APOE*3/*3 homozygotes, APOE*4 allele patients had higher mean levels of low-density lipoprotein (LDL) cholesterol (p = 0.014), apoB (p = 0.031), lower mean levels of apoA1 (p = 0.043), and a trend of higher mean level of total cholesterol (p = 0.084). Thirty-one percent of patients with CAD had the APOE*4 allele compared to 26% with the APOE*3 allele, but this difference was not significant. Compared with APOE*3/*3 homozygotes, patients with the APOE*4 allele had 1.3 times higher risk for CAD after ignoring dyslipidemia, but this risk was modified after adjusting for dyslipidemia. In conclusion, among dyslipidemic patients, carriers of APOE*4 compared to homozygous carriers of APOE*3 had significantly higher levels of LDL cholesterol and apoB, but no relationship with CAD was found.